Aligos Therapeutics, Inc.

Historical 13F Holders

Symbol
ALGS
CUSIP
01626L204
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 01626L204 since 12/18/2024, largest first.

Filer % of Class Filed
Alyeska Investment Group, L.P. 13G
10.0% 5/15/2025
Event 3/31/2025
Blatt Lawrence 13D 5.6% 6/24/2026
Event 6/16/2026
Sio Capital Management, LLC 13G/A 5.5% 2/11/2026
Event 12/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Armistice Capital, LLC 13G/A
4.99% 2/14/2025
Event 12/31/2024
Woodline Partners LP 13G/A 4.4% 5/15/2026
Event 3/31/2026
EcoR1 Capital, LLC 13G/A
3.9% 5/15/2025
Event 3/31/2025
Adage Capital Management, L.P. 13G/A
3.9% 8/12/2025
Event 6/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 1 4.00 $23.00
2026 Q2 31 2.29 M $13.2 M
2026 Q1 34 2.78 M $20.6 M
2025 Q4 40 2.81 M $26.2 M
2025 Q3 35 2.65 M $26.0 M
2025 Q2 39 2.71 M $19.5 M
2025 Q1 37 3.30 M $27.1 M
2024 Q4 34 1.62 M $64.5 M
2024 Q3 29 1.69 M $14.7 M